<h4>Background</h4>The BRAF V600E mutation is a rare genetic alteration in cholangiocarcinoma for which sequential therapy with immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors may be effective. Here, MAP2K7 is linked to cholangiocarcinoma.